Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2

Cancer Research

Volumn 72, Issue 14, 2012, Pages 3582-3592

  He, Meilan ^a,c   Zhang, Wei ^c   Bakken, Thomas ^a   Schutten, Melissa ^b,d   Toth, Zsolt ^c   Jung, Jae U ^c   Gill, Parkash ^c   Cannon, Mark ^a,b   Gao, Shou Jiang ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN B2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR EZH2;

ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MODIFICATION; ENDOTHELIUM CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; HUMAN TISSUE; KAPOSI SARCOMA; LANA GENE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR VASCULARIZATION; UPREGULATION; VFLIP GENE; VIRUS GENE; VIRUS INFECTION;

ANGIOGENESIS INDUCING AGENTS; ANTIGENS, VIRAL; CELL LINE; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; EPHRIN-B2; GENE EXPRESSION REGULATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; SARCOMA, KAPOSI; TRANSCRIPTION FACTORS; UP-REGULATION; VIRAL PROTEINS; VIRUS LATENCY;

EID: 84863969631     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2876     Document Type: Article

References (49)

1. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-19.
2. Ciufo DM, Cannon JS, Poole LJ, Wu FY, Murray P, Ambinder RF, et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol 2001;75:5614-26. (Pubitemid 32488155)
3. Gao SJ, Deng JH, Zhou FC. Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J Virol 2003;77:9738-49.
4. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, et al. Lymphatic reprogramming of blood vascular endotheliumby Kaposi's sarcoma-associated herpesvirus. Nat Genet 2004;36:683-5. (Pubitemid 38886627)
5. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, et al. Kaposi's sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004;36:687-93. (Pubitemid 38886628)
6. Carroll PA, Brazeau E, Lagunoff M. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 2004;328:7-18. (Pubitemid 39221907)
7. Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, Greene W, et al. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007;81:3980-91. (Pubitemid 46586893)
8. Qian LW, Xie J, Ye F, Gao SJ. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 2007;81:7001-10. (Pubitemid 46986636)
9. Qian LW, Greene W, Ye F, Gao SJ. Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. J Virol 2008; 82:11902-12.
10. Shin YC, Joo CH, Gack MU, Lee HR, Jung JU. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Res 2008;68:1751-9. (Pubitemid 351416560)
11. Wang L, Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 2008;68: 4640-8.
12. Xie J, Pan H, Yoo S, Gao SJ. Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. J Virol 2005;79:15027-37. (Pubitemid 43032284)
13. Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A, et al. Ephrin B2 expression in Kaposi's sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood 2005;105:1310-8. (Pubitemid 40170908)
14. Sivakumar R, Sharma-Walia N, Raghu H, Veettil MV, Sadagopan S, Bottero V, et al. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 2008;82:1759-76. (Pubitemid 351206926)
15. Iso T, Maeno T, Oike Y, Yamazaki M, Doi H, Arai M, et al. Dll4-selective Notch signaling induces ephrinB2 gene expression in endothelial cells. Biochem Biophys Res Commun 2006;341:708-14. (Pubitemid 43177547)
16. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010;7: 299-313.
17. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4. (Pubitemid 43255707)
18. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011;19:86-100.
19. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar- Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419: 624-9.
20. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007;27: 5105-19. (Pubitemid 47068285)
21. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012;109: 2989-94.
22. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18: 185-97.
23. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 2011;43:285-98.
24. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, et al. miR-101 is down-regulated in glioblastoma resulting in EZH2- induced proliferation, migration, and angiogenesis. Oncotarget 2010; 1:710-20.
25. Gunther T, Grundhoff A. The epigenetic landscape of latent Kaposi's sarcoma-associated herpesvirus genomes. PLoS Pathog 2010;6: e1000935.
26. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, et al. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 2010;6:e1001013.
27. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi's sarcoma pathogenesis. J Clin Invest 2004;113:124-36. (Pubitemid 38541639)
28. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7. (Pubitemid 30036389)
29. He M, Bakken T, Kassimova A, Boshoff C, Philpott N, Cannon ML. Focal adhesion kinase is required for KSHV vGPCR signaling. Mol Carcinog 2011 [Epub ahead of print].
30. Della Bella S, Taddeo A, Calabro ML, Brambilla L, Bellinvia M, Bergamo E, et al. Peripheral blood endothelial progenitors as potential reservoirs of Kaposi's sarcoma-associated herpesvirus. PLoS One 2008;3: e1520.
31. Trenkmann M, Brock M, Gay RE, Kolling C, Speich R, Michel BA, et al. Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann Rheum Dis 2011;70:1482-8.
32. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ, et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006;107: 3295-302.
33. Matta H, Chaudhary PM. Activation of alternative NF-kappa Bpathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci U S A 2004;101:9399-404. (Pubitemid 38812886)
34. Konrad A, Wies E, Thurau M, Marquardt G, Naschberger E, Hentschel S, et al. Asystems biology approach to identify the combination effects of human herpesvirus 8 genes on NF-kappaB activation. J Virol 2009;83:2563-74.
35. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012;106:243-7.
36. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, et al. The role of Ephs, Ephrins, and growth factors in Kaposi's sarcoma and implications of EphrinB2 blockade. Blood 2009;113:254-63.
37. Delgado-Olguin P, Huang Y, Li X, Christodoulou D, Seidman CE, Seidman JG, et al. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet 2012;44:343-7.
38. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010;116:5247-55.
39. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35. (Pubitemid 37279943)
40. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112:4202-12.
41. Tang X,MilyavskyM, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-69. (Pubitemid 39093021)
42. Ye FC, Zhou FC, Xie JP, Kang T, Greene W, Kuhne K, et al. Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol 2008;82:4235-49. (Pubitemid 351563661)
43. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002;3:475-86. (Pubitemid 34733429)
44. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, Follenzi A, et al. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 2009;114: 1707-16.
45. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010;465:487-91.
46. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010;465:483-6.
47. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, et al. EZH2- mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res 2011;71: 4028-39.
48. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010;115:3098-108.
49. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, et al. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol Cell 2011;43:798-810.